Last reviewed 2026-05-25 · How we verify

Sulglycotide (SULGLICOTIDE)

Phase 2 active Recombinant protein ✓ Verified May 2026

Sulglycotide (generic name: SULGLICOTIDE) is a sulglicotide drug. It is currently in Phase 2 development.

Sulglycotide works by binding to a specific target, although its exact mechanism of action is currently unknown.

Sulglycotide is a protein modality. It is also known by the synonyms DEMUCINE, GLIPTIDE, SULGLICOTIDA, SULGLICOTIDE, and SULGLICOTIDE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULGLICOTIDE
Drug class	sulglicotide
Modality	Recombinant protein
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and sulglycotide is a key that fits into those locks. When it binds, it can either unlock or block the normal functioning of the cell, depending on the type of lock and the key's shape. This can help to either slow down or speed up certain processes in the body, but the exact details of how it works are still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sulglycotide CI brief — competitive landscape report
Sulglycotide updates RSS · CI watch RSS

Frequently asked questions about Sulglycotide

What is Sulglycotide?

Sulglycotide (SULGLICOTIDE) is a sulglicotide drug.

How does Sulglycotide work?

Sulglycotide works by binding to a specific target, although its exact mechanism of action is currently unknown.

What is the generic name of Sulglycotide?

SULGLICOTIDE is the generic (nonproprietary) name of Sulglycotide.

What drug class is Sulglycotide in?

Sulglycotide belongs to the sulglicotide class. See all sulglicotide drugs at /class/sulglicotide.

What development phase is Sulglycotide in?

Sulglycotide is in Phase 2.

Drug class: All sulglicotide drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing